

# John Bartlett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10636757/publications.pdf>

Version: 2024-02-01

36  
papers

10,645  
citations

236925

25  
h-index

377865

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

12456  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 775-783.	2.8	20
2	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunohistochemistry biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
3	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	0
4	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2105-2122.	1.6	1,362
5	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1364-1382.	2.5	644
6	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Modern Pathology</i> , 2017, 30, 509-518.	5.5	32
7	HER2 status predicts for upfront AI benefit: ATRANS-AIOG meta-analysis of 12,129 patients from AATAC, BIG 1-98 and TEAM with centrally determined HER2. <i>European Journal of Cancer</i> , 2017, 79, 129-138.	2.8	21
8	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. <i>Breast Cancer Research</i> , 2017, 19, 55.	5.0	29
9	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	2.8	53
10	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1302-1304.	1.6	31
11	A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. <i>Oncotarget</i> , 2015, 6, 31693-31701.	1.8	6
12	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 241-256.	2.5	961
13	Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2951-2958.	1.6	101
14	Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?. <i>Breast Cancer Research</i> , 2013, 15, R31.	5.0	3
15	An International Ki67 Reproducibility Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1897-1906.	6.3	498
16	Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2257-2264.	1.6	64
17	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 3997-4013.	1.6	3,276
18	Authors' Reply. <i>Journal of Pathology</i> , 2013, 229, e2-3.	4.5	0

#	ARTICLE	IF	CITATIONS
19	Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis. European Journal of Cancer, 2013, 49, 297-304.	2.8	25
20	Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. Journal of Clinical Oncology, 2012, 30, 4477-4484.	1.6	58
21	Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. Journal of Pathology, 2012, 227, 481-489.	4.5	29
22	Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer. Histopathology, 2012, 60, 369-371.	2.9	17
23	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2011, 103, 1656-1664.	6.3	1,505
24	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet, The, 2011, 377, 321-331.	13.7	346
25	Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved Utility. Journal of Clinical Oncology, 2011, 29, 3715-3716.	1.6	11
26	Breast Cancer Biomarkers. , 2011, , 306-316.		1
27	Reply to V. Arena et al. Journal of Clinical Oncology, 2009, 27, e9-e10.	1.6	3
28	External Quality Assurance of HER2 FISH and ISH Testing. American Journal of Clinical Pathology, 2009, 131, 106-111.	0.7	35
29	Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology, 2009, 54, 254-257.	2.9	57
30	Human Epidermal Growth Factor Receptor Dimerization Analysis in Breast Cancer Diagnosis. Molecular Diagnosis and Therapy, 2009, 13, 359-365.	3.8	3
31	Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. Journal of Clinical Oncology, 2009, 27, 1323-1333.	1.6	470
32	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, The, 2009, 373, 1681-1692.	13.7	168
33	Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. Journal of Clinical Oncology, 2008, 26, 5027-5035.	1.6	90
34	Determination of HER2 Amplification by In Situ Hybridization. American Journal of Clinical Pathology, 2008, 130, 920-926.	0.7	28
35	Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) – Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4423-4430.	1.6	66
36	Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling. Breast Cancer Research, 2004, 6, R246-51.	5.0	120